Inhibition of COX2 enhances the chemosensitivity of dichloroacetate in cervical cancer cells

摘要: // Bo Li 1, * , Xinzhe Haojun Xiong 1 Peng Zhou Zhenhong Ni Teng Yang Yan Zhang Yijun Zeng Jintao He 2 Fan Nan Yuting Wang Yingru Zheng 3 and Fengtian Department of Biochemistry Molecular Biology, College Basic Medical Sciences, Third Military University, Chongqing 400038, China Battalion 17 Students, Preventive Medicine, Obstetrics Gynecology, Daping Hospital Research Institute Surgery, 400042, These authors have contributed equally to this work Correspondence to: Zheng, email: zyrdaping@aliyun.com He, hefengtian06@aliyun.com Keywords: dichloroacetate, COX2, celecoxib, QKI, cervical cancer Received: February 07, 2017      Accepted: May 06, Published: June 16, 2017 ABSTRACT Dichloroacetate (DCA), a traditional mitochondria-targeting agent, has shown promising prospect as sensitizer in fighting against malignancies including cancer. But it is unclear about the effect DCA alone on tumor. Moreover, previous reports demonstrated that increased cyclooxygenase-2 (COX2) expression associated with chemoresistance poor prognosis However, still unknown whether COX2 can affect sensitivity cells. In study, we found cells were insensitive DCA. Furthermore, for first time revealed could upregulate which impeded chemosensitivity Mechanistic study showed reduced level RNA binding protein quaking (QKI), leading decay suppression mRNA subsequent elevation protein. Inhibition using celecoxib sensitize repressing growth both vitro vivo . results indicate novel resistance factor DCA, combination may be beneficial treatment